Vaccine最新文献

{"title":"Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation","authors":"Kate Emary ,&nbsp;Adwoa D. Bentsi-Enchill ,&nbsp;Birgitte K. Giersing ,&nbsp;Melita Gordon ,&nbsp;Helen Dale ,&nbsp;Esmelda B. Chirwa ,&nbsp;Peter Johnston ,&nbsp;Calman A. MacLennan ,&nbsp;Samuel Kariuki ,&nbsp;Jean-Louis Excler ,&nbsp;Jerome H. Kim ,&nbsp;Robert W. Kaminski ,&nbsp;Annelies Wilder-Smith ,&nbsp;the iNTS vaccine Consultation Expert Group","doi":"10.1016/j.vaccine.2025.127008","DOIUrl":"10.1016/j.vaccine.2025.127008","url":null,"abstract":"<div><div>Invasive disease caused by non-typhoidal <em>Salmonella</em> serovars (iNTS) occurs with increased risk in the presence of other comorbidities such as malaria, HIV, malnutrition, anaemia and sickle cell disease. While infection with non-typhoidal (NTS) serovars often results in self-limited enterocolitis in high-income settings, in sub-Saharan Africa (SSA) where these risk-comorbidities are common, an invasive (iNTS) disease phenotype is seen, associated with up to 20 % case-fatality ratio, and antimicrobial resistance is both significant and growing. The need to evaluate the potential public health value of vaccines against iNTS disease is increasingly being recognized, and several candidate vaccines are in early development. A better understanding of the global burden and epidemiology of iNTS disease, as well as the potential public health and socio-economic benefits that iNTS vaccines may offer is fundamental to support and justify the investments in vaccine development. In addition, the pathways for licensure, policy recommendations and eventual vaccine prioritization and use in low- and middle-income countries (LMICs) need to be defined.</div><div>Here, we report on the proceedings of an expert consultation held on 29 November – 1 December 2021 as part of an overall project to develop a Full Value of Vaccines Assessment (FVVA) for iNTS vaccines and in addition to more recent iNTS vaccine developments. Experts at the consultation reviewed the current evidence on iNTS disease and discussed knowledge gaps to be addressed to accelerate vaccine development, licensure and introduction, as well as LMIC perspectives on potential iNTS vaccine use and demand. The learnings from this consultation are critical inputs to inform remaining work under the iNTS FVVA project.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127008"},"PeriodicalIF":4.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“It's easier to deal with the vaccines you know than the ones you don't know”: A qualitative study on healthcare workers' vaccine confidence in Nigeria","authors":"Ayobami A. Bakare ,&nbsp;Elisa Gobbo ,&nbsp;Kofoworola O. Akinsola ,&nbsp;Carina King ,&nbsp;Julius Salako ,&nbsp;Damola Bakare ,&nbsp;Halima Usman ,&nbsp;Claudia Hanson ,&nbsp;Adegoke G. Falade ,&nbsp;Sibylle Herzig van Wees","doi":"10.1016/j.vaccine.2025.127020","DOIUrl":"10.1016/j.vaccine.2025.127020","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127020"},"PeriodicalIF":4.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions of non-needle-based vaccination devices in the state of Georgia","authors":"Logan Melot ,&nbsp;Erica Thyfault ,&nbsp;Kyra Hester ,&nbsp;Mark R. Prausnitz ,&nbsp;Robert A. Bednarczyk","doi":"10.1016/j.vaccine.2025.127038","DOIUrl":"10.1016/j.vaccine.2025.127038","url":null,"abstract":"<div><h3>Background</h3><div>Vaccination is important for controlling infectious disease; however, there are logistical barriers associated with needle and syringe-based vaccination. Non-needle-based vaccination methods could address many of these barriers and are in pre-clinical and clinical development. New technology is sometimes followed by hesitancy, affecting acceptance and uptake, highlighting the importance of understanding the perceptions of vaccine delivery methods by potential vaccine recipients.</div></div><div><h3>Methods</h3><div>To understand perceptions of non-needle-based vaccination methods in the state of Georgia, we surveyed 427 Georgia residents. Respondents were asked about their perceptions of vaccines and new medical technology, willingness to accept a non-needle-based vaccine, and whether they would recommend specific vaccination devices.</div></div><div><h3>Results</h3><div>Race and ethnicity were found to impact vaccine hesitancy and trust in new medical developments hesitancy. Of 427 participants, 29.3 % were more likely to accept non-needle-based devices over needle/syringe, 35.1 % were just as likely to accept, 14.4 % were unsure, and 20.6 % indicated that non-needle-based methods would not make them more likely to receive a vaccine. Race, urbanization, insurance status, vaccine hesitancy, and trust in new medical developments affected willingness to accept a non-needle-based vaccine. Needle/syringe vaccine devices were the most accepted method based on a picture and short description (77.6 %), inhaled vaccine devices were the least recommended (46.8 %); nasal spray (64.3 %), jet injector (60.0 %), skin patch (57.3 %), and oral delivery (54.0 %) were between these values.</div></div><div><h3>Conclusions</h3><div>While needle/syringe is the preferred method of vaccination, there are clear preferences among non-needle-based vaccine delivery methods; however, demographic factors that are associated should be considered as these devices move through clinical testing. Our future work will involve in-depth interviews to further identify important themes affecting vaccine acceptance in Georgia. Due to potential hesitancy, we need to strengthen our understanding of themes associated with vaccine perceptions to enable design of accurate and persuasive materials for physicians and patients.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127038"},"PeriodicalIF":4.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of potential vaccines for use with microarray patches in low- and middle-income countries: An assessment from the Vaccine Innovation Prioritisation Strategy Alliance","authors":"Collrane Frivold ,&nbsp;Birgitte Giersing ,&nbsp;Jean-Pierre Amorij ,&nbsp;Mercy Mvundura ,&nbsp;Mateusz Hasso-Agopsowicz ,&nbsp;Jessica Joyce Mistilis ,&nbsp;Kristen Earle ,&nbsp;Courtney Jarrahian ,&nbsp;Marion Menozzi-Arnaud ,&nbsp;Tiziana Scarna","doi":"10.1016/j.vaccine.2025.126996","DOIUrl":"10.1016/j.vaccine.2025.126996","url":null,"abstract":"<div><h3>Introduction</h3><div>Microarray patches (MAPs) have the potential to increase equitable vaccine coverage in low- and middle-income countries (LMICs). However, MAP developers and vaccine manufacturers have identified a barrier to development of MAPs for global health applications: the need for guidance on which vaccine MAPs would be of value to LMIC immunization programs. To address this gap, the Vaccine Innovation Prioritisation Strategy (VIPS) Alliance conducted a prioritization process to identify high-priority vaccines that could be delivered via MAPs in LMICs.</div></div><div><h3>Methods</h3><div>We first compiled a reference list of vaccine targets through desk research, then filtered these targets based on route of administration, market distribution, existing interest from a global/regional health organization, whether the vaccine would address a specific global health priority or stakeholder agenda, development status, and potential MAP use cases. To further down-select the list, we consulted an external advisory group and evaluated the potential regulatory pathway, programmatic impact, and financial sustainability to define two priority levels.</div></div><div><h3>Results</h3><div>From a reference list of 91 vaccine targets, we identified 21 with applicability to LMICs, which were further down-selected to a VIPS priority list of 11 vaccine targets grouped by priority level. Priority group 1 included vaccines against hepatitis B virus, measles-rubella/measles-mumps-rubella viruses, human papillomavirus, rabies virus, yellow fever, influenza virus (seasonal and pandemic), and SARS-CoV-2. Priority group 2 included vaccines against Group B streptococcus, <em>Neisseria meningitidis</em> A,C,W,Y,(X), <em>Salmonella Typhi</em>, and <em>Streptococcus pneumoniae</em>.</div></div><div><h3>Conclusions</h3><div>These vaccine MAP priorities will inform the investment decisions of MAP developers, vaccine manufacturers, donors, and global health partners to better respond to country needs when designing their MAP portfolios. By providing a holistic assessment of the potential drivers for and key risks of developing specific vaccine MAPs, our findings have the potential to promote MAP development activities for vaccines that are priorities for LMICs.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 126996"},"PeriodicalIF":4.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sociodemographic differences in parental hesitancy to the COVID-19 vaccine","authors":"Courtney K. Blackwell ,&nbsp;Traci Bekelman ,&nbsp;Shivani Bakre ,&nbsp;Lisa P. Jacobson ,&nbsp;Nissa R. Towe-Goodman ,&nbsp;Johnnye Lewis ,&nbsp;Debra A. MacKenzie ,&nbsp;Qeturah Anderson ,&nbsp;Delma-Jean Watts ,&nbsp;Kaja Z. LeWinn ,&nbsp;for the ECHO Cohort Consortium","doi":"10.1016/j.vaccine.2025.127041","DOIUrl":"10.1016/j.vaccine.2025.127041","url":null,"abstract":"<div><h3>Objective(s)</h3><div>To identify sociodemographic patterns in pediatric COVID-19 vaccination status and parental vaccine hesitancy reasons.</div></div><div><h3>Study design</h3><div>Cross-sectional survey data was collected from 5103 US parents of 6 month to 17-year-olds from the NIH Environmental influences on Child Health Outcomes (ECHO) study. We used chi-square tests to examine sociodemographic differences between vaccinated and unvaccinated children and between vaccine-hesitant and non-hesitant parents. We used risk ratios (RRs) from adjusted multivariable Poisson regressions to examine associations between sociodemographic characteristics and vaccine hesitancy reasons.</div></div><div><h3>Results</h3><div>Less than half (41.7 %) of children had received at least one dose of the COVID-19 vaccine. Only 1 % of parents who were unsure or had no plans to vaccinate their children (“vaccine hesitant”) cited resource barriers (e.g., transportation, cost). Instead, vaccine-hesitant parents reported concerns about side effects (general: 53.1 %; long-term: 56.2 %); believed their child did not need the vaccine due to low risk (33.7 %) or prior infection (21 %); perceived there was insufficient vaccine testing in children (24 %) and in racially/ethnically diverse populations (9.5 %); and lacked trust in healthcare provider recommendations (9 %). Vaccine-hesitant parents of Indigenous and Black children were less likely to report side effect concerns (general: RR 0.65–0.87; long-term: RR 0.55–0.66); higher-income and higher-educated vaccine-hesitant parents were ∼ 1.5–2 times more likely to say their child was at low risk.</div></div><div><h3>Conclusion(s)</h3><div>Safety concerns and perceived low risk influenced parental COVID-19 vaccination hesitancy, not resource barriers. Important sociodemographic differences can inform future approaches to public health campaigns to propel swift action during a public health crisis to help reduce disease burden and spread.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127041"},"PeriodicalIF":4.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular and WGS-based characterization of invasive Neisseria meningitidis isolates collected in Belgium (2016–2022) and MenB-FHbp vaccine coverage estimation of serogroup B","authors":"Nathalie Goeders ,&nbsp;Kevin Vanneste ,&nbsp;Nancy H.C. Roosens ,&nbsp;Bert Bogaerts ,&nbsp;Wesley Mattheus","doi":"10.1016/j.vaccine.2025.127026","DOIUrl":"10.1016/j.vaccine.2025.127026","url":null,"abstract":"<div><div>Invasive meningococcal disease (IMD) caused by <em>Neisseria meningitidis</em> can result in life-threatening meningitis and septicaemia. There are twelve serogroups of <em>N. meningitidis</em>, but most cases of IMD are caused by serogroups A, B, C, W, X and Y. In Europe, serogroup B (MenB) accounts for 51 % of documented cases as recently reported by the European Centre for Disease Prevention and Control (ECDC). As a major cause of IMD, genomic surveillance of circulating MenB strains and assessment of the potential impact of vaccination programs could help inform public health policy. In this study, a collection of 493 strains was analysed, collected in Belgium by the National Reference Centre between 2016 and 2022. Slide agglutination was used for serogroup determination and whole genome sequencing (WGS) was used to further characterize these strains. The observed serogroups were: MenB (<em>n</em> = 281), MenY (<em>n</em> = 95), MenW (<em>n</em> = 83), MenC (<em>n</em> = 30), non-groupable isolates (n = 2), MenE (<em>n</em> = 1) and MenX (n = 1). A higher prevalence of MenY and MenW was observed in older adults. MenB isolates were grouped into 110 sequence types (STs), 89 of which belonged to 16 clonal complexes (CCs). Coverage of the MenB-FHbp vaccine (Trumenba, bivalent rLP2086; Pfizer Inc., New York, NY, USA ipv Philadelphia) was predicted using the Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) index. Of the 281 MenB strains collected between 2016 and 2022, 89.1 % (lower limit – upper limit: 78.6–100.0 %) were predicted by MenDeVAR to be covered by the vaccine. This study highlights the benefits of a pathogen surveillance program and the need for experimental characterization of continuously evolving antigenic variants.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127026"},"PeriodicalIF":4.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next-generation immunotherapeutic strategy and clinical advances of vaccines against nicotine addiction","authors":"Kun Yan,&nbsp;Shan Xu,&nbsp;Hufeng Fang,&nbsp;Hao Yang,&nbsp;Dan Su","doi":"10.1016/j.vaccine.2025.127036","DOIUrl":"10.1016/j.vaccine.2025.127036","url":null,"abstract":"<div><div>Smoking causes death of millions of people every year. However, available therapies for nicotine addiction are partially effective and exhibit frequent side effects. Thus vaccines targeted at drug nicotine not brain offer a promising strategy to treat nicotine addiction. They cannot pass blood-brain barrier, avoiding serious side effects relevant with central nervous system. The specific nicotine antibody produced by vaccines would convert to complex after combined with nicotine in serum, decreasing or even blocking the distribution of nicotine in brain. This review summarizes the pre-clinical and clinical advances of nicotine vaccines and then addresses future directions of nicotine vaccine and the practical aspects of deployments.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127036"},"PeriodicalIF":4.5,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rapid human vaccine process development map outlining lessons learnt from ChAdOx1 nCoV-19 vaccine during the COVID-19 pandemic","authors":"Michael James Francis","doi":"10.1016/j.vaccine.2025.127040","DOIUrl":"10.1016/j.vaccine.2025.127040","url":null,"abstract":"<div><div>In 2015 the UK Vaccine Network through its Working Group 3 began the creation of a website describing the conventional development of human and veterinary vaccines, which routinely takes several years to complete from concept through to licensure, in the form of process development maps. This website has proved to be a valuable resource for those involved in commercial vaccine development and it has also highlighted the potential bottlenecks within the processes. However, during the COVID-19 pandemic, vaccines were created, licenced and administered within 1 year of the SARS-CoV-2 virus sequence being made available to researchers globally, through the use of novel platform technologies, such as viral vectors and mRNA. The paper describes the updating of this vaccine process development website and the inclusion of a rapid development map with 14 Stages based knowledge gained during the development of the University of Oxford/Astra Zeneca ChAdOx-1 vectored COVID-19 vaccine. The map captures the key steps required to expedite human vaccine development in the face of a pandemic threat from pre-clinical discovery, vaccine platform development, regulatory review and approval through to the administration of the first dose in humans.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127040"},"PeriodicalIF":4.5,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Humoral immune response to 10-valent pneumococcal conjugate vaccine (PCV10) in individuals with type 2 diabetes mellitus","authors":"Izaz Ahmad ,&nbsp;Robert Burton ,&nbsp;Rozina Arshad ,&nbsp;Bilal Bin Younis ,&nbsp;Shaper Mirza","doi":"10.1016/j.vaccine.2025.127029","DOIUrl":"10.1016/j.vaccine.2025.127029","url":null,"abstract":"<div><h3>Background</h3><div>Pneumococcal infections pose a significant health problem in individuals with comorbid conditions such as Type 2 diabetes mellitus. Although pneumococcal vaccines are recommended in individuals with type 2 diabetes, there is a lack of data on the immunogenicity of pneumococcal vaccines in the type 2 diabetes population. This pilot study was therefore developed to determine if the humoral immune response to the 10-valent pneumococcal conjugate vaccine (PCV10) in those with and without type 2 diabetes is comparable.</div></div><div><h3>Methods</h3><div>A total of 40 (24 with type 2 diabetes and 16 without type 2 diabetes) adults were immunized with PCV10. WHO reference ELISA and multiplexed opsonophagocytic killing assay (MOPA) were used to measure the concentration and functionality of serotype-specific IgG at baseline and 14 days, 1 month, and 8 months post-vaccination.</div></div><div><h3>Results</h3><div>The geometric mean IgG concentrations and opsonic titers increased significantly in post-immunization (T1–14 days, T2–1 month, and T3–8 month) serum samples compared to baseline (T0) in individuals with and without type 2 diabetes. In both groups, the highest post-immunization IgG concentrations were measured for serotype 19F at T2. Individuals with type 2 diabetes showed significantly lower IgG concentrations and opsonic titers for serotype 19F and 9V post-immunization compared to age and sex-matched non-diabetes individuals. Serotype-specific IgG concentrations declined rapidly in those with type 2 diabetes at 8 months post-immunization. Obese diabetes individuals had lower IgG concentrations compared to non-Obese individuals with type 2 diabetes.</div></div><div><h3>Conclusion</h3><div>Individuals with type 2 diabetes demonstrated a significant protective humoral immune response to the 10-valent pneumococcal conjugate vaccine (PCV10); however, the response was comparatively less robust and declined faster in those with type 2 diabetes compared to age and sex-matched non-diabetes controls.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127029"},"PeriodicalIF":4.5,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of lymphocyte miRNA expression on influenza vaccine-induced immunity","authors":"Iana H. Haralambieva ,&nbsp;Tamar Ratishvili ,&nbsp;Krista M. Goergen ,&nbsp;Diane E. Grill ,&nbsp;Whitney L. Simon ,&nbsp;Jun Chen ,&nbsp;Inna G. Ovsyannikova ,&nbsp;Gregory A. Poland ,&nbsp;Richard B. Kennedy","doi":"10.1016/j.vaccine.2025.127023","DOIUrl":"10.1016/j.vaccine.2025.127023","url":null,"abstract":"<div><div>Alterations of gene expression by miRNAs contribute substantially to genetic regulation and cellular functions. We conducted a comprehensive study in 53 individuals before and after seasonal inactivated influenza vaccine to characterize lymphocyte-specific miRNA expression (in purified B cells, CD4+ T cells, CD8+ T cells, and NK cells) and its effect on influenza vaccine-induced immune outcomes (hemagglutination inhibition antibody titers/HAI, viral neutralizing antibody titers /VNA, and memory B cell ELISPOT). Overall, we observed relatively stable miRNA expression before and after influenza vaccination. Statistical analysis uncovered three baseline miRNAs (miR-150-3p, miR-629-5p, and miR-4443) that were significantly correlated with influenza vaccine-induced immune outcomes in different cell types. Predictive modeling of influenza vaccine-induced HAI/VNA titers identified a set of specific baseline miRNAs in CD4⁺ T cells as factors predictive of antibody responses. A pathway enrichment analysis on the putative target genes revealed several regulated signaling pathways and functions: TGF-β signaling, PI3K-Akt signaling, p53 signaling, MAPK signaling, TNF signaling, and C-type lectin receptor signaling, as well as cell adhesion and adherens junctions, and antiviral host response. In conclusion, our study offers evidence for the role of epigenetic modification (miRNAs) on influenza vaccine-induced immunity. After validation, identified miRNAs may serve as potential biomarkers of immune response after influenza vaccination.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127023"},"PeriodicalIF":4.5,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}